Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Final draft guidance

Final draft guidance (PDF 208 KB)

Committee papers (PDF 10.12 MB)

Public committee slides (PDF 1.49 MB)

Equality impact assessment (PDF 143 KB)

Register of interests (PDF 134 KB)

Final scope (PDF 191 KB)

Final stakeholder list (PDF 174 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 326 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Draft matrix post referral (PDF 171 KB)

Draft scope post referral (PDF 199 KB)